Other
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount
Vertex Pharmaceuticals Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount remained flat by 0.0% to $15.48M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionOther
CategoryEfficiency
SignalHigher is better
VolatilityStable
First reportedQ1 2025
Last reportedQ4 2025Feb 13, 2026
How to read this metric
Higher values indicate a larger portion of earnings are shielded from tax, improving net profitability.
Detailed definition
The tax benefit derived from income streams that are legally exempt from taxation. This reduces the effective tax rate b...
Peer comparison
Common in companies with significant investment income or specific tax-exempt structures.
Metric ID:
other_income_tax_reconciliation_tax_exempt_incomeHistorical Data
1 years
| FY'25 | |
|---|---|
| Value | $61.90M |
Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's effective income tax rate reconciliation, tax exempt income, amount?
- Vertex Pharmaceuticals (VRTX) reported effective income tax rate reconciliation, tax exempt income, amount of $15.48M in Q4 2025.
- What does effective income tax rate reconciliation, tax exempt income, amount mean?
- The tax savings from income that is not subject to taxation.